TY - JOUR
T1 - Vitamin K2 therapy for myelodysplastic syndrome
AU - Abe, Yasunobu
AU - Muta, Koichiro
AU - Hirase, Nobuhisa
AU - Choi, Ilseung
AU - Matsushima, Takamitsu
AU - Hara, Keiichi
AU - Taguchi, Fumihiro
AU - Suematsu, Eiichi
AU - Shibata, Keisuke
AU - Uike, Naokuni
AU - Nishimura, Junji
AU - Nawata, Hajime
PY - 2002/2
Y1 - 2002/2
N2 - Vitamin K2 is reported to induce apoptosis or differentiation of leukemic cell lines in vitro. We administered a vitamin K2 analog, menatetrenone, at 45 mg daily to 23 patients with myelodysplastic syndrome (MDS): 13 patients with RA, 2 with RARS, 6 with RAEB and 2 with RAEB-T. Good response (GR) and partial response (PR) were defined as an increase of hemoglobin concentration exceeding 2 g/dl and 1-2 g/dl without transfusion, respectively. Six of the RA patients showed improvement of anemia (GR, 3 patients; PR, 3 patients). RA patients who did not have a hypocellular bone marrow and were transfusion-independent tended to be responsive to vitamin K2 therapy in combination with vitamin D3 or anabolic steroids. No adverse effect of vitamin K2 was observed, and the time required to obtain the hematological response was short, being 3 months on average. We believe that vitamin K2 therapy has potential as a treatment for patients with MDS.
AB - Vitamin K2 is reported to induce apoptosis or differentiation of leukemic cell lines in vitro. We administered a vitamin K2 analog, menatetrenone, at 45 mg daily to 23 patients with myelodysplastic syndrome (MDS): 13 patients with RA, 2 with RARS, 6 with RAEB and 2 with RAEB-T. Good response (GR) and partial response (PR) were defined as an increase of hemoglobin concentration exceeding 2 g/dl and 1-2 g/dl without transfusion, respectively. Six of the RA patients showed improvement of anemia (GR, 3 patients; PR, 3 patients). RA patients who did not have a hypocellular bone marrow and were transfusion-independent tended to be responsive to vitamin K2 therapy in combination with vitamin D3 or anabolic steroids. No adverse effect of vitamin K2 was observed, and the time required to obtain the hematological response was short, being 3 months on average. We believe that vitamin K2 therapy has potential as a treatment for patients with MDS.
UR - http://www.scopus.com/inward/record.url?scp=0036482674&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036482674&partnerID=8YFLogxK
M3 - Article
C2 - 11925874
AN - SCOPUS:0036482674
SN - 0485-1439
VL - 43
SP - 117
EP - 121
JO - [Rinshō ketsueki] The Japanese journal of clinical hematology
JF - [Rinshō ketsueki] The Japanese journal of clinical hematology
IS - 2
ER -